Organization
Vanderbilt University School of Medicine
11 abstracts
Abstract
Assessing the true cost of cancer screening: Comparing hospital prices to claims remittance data for common cancer screening tests at top-ranked US hospitals.Org: Vanderbilt University School of Medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Tennessee Oncology, PLLC, Owen Graduate School of Management,
Abstract
Impact of maintenance pemetrexed cessation on clinical outcomes of patients with metastatic non-squamous NSCLC.Org: Vanderbilt University School of Medicine, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, Department of Medicine, Icahn School of Medicine at Mount Sinai, Vanderbilt University Medical Center,
Abstract
Lurbinectedin versus platinum rechallenge in relapsed extensive stage small cell lung cancer: A retrospective cohort study.Org: Vanderbilt University School of Medicine, Vanderbilt University Medical Center,
Abstract
Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients (pts) with cardiac metastases (mets) from solid tumors.Org: Yale Cancer Center, Yale School of Medicine, New Haven, CT, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, University of Texas MD Anderson Cancer Center,
Abstract
Oncologists’ receipt of pharmaceutical industry payments and use of non-recommended and low-value cancer care services.Org: Memorial Sloan Kettering Cancer Center, Vanderbilt University School of Medicine, DELFI Diagnostics, Medical College of Wisconsin,
Abstract
Racial disparities in aging-related comorbidity among breast cancer survivors.Org: Vanderbilt University School of Medicine, Division of Epidemiology and Community Health, Department of Medicine, Icahn School of Medicine at Mount Sinai, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center,
Abstract
Association of social vulnerability with delays in starting guideline-adherent adjuvant therapy among patients with head and neck cancer.Org: Medical University of South Carolina Hollings Cancer Center, Washington University School of Medicine in St Louis, Vanderbilt University School of Medicine, Lewis Katz School of Medicine at Temple University, Henry Ford Health System,
Abstract
Long-term outcomes of chronic immune-related adverse events from adjuvant anti-PD-1 therapy for high-risk resected melanoma.Org: Vanderbilt University School of Medicine, Massachusetts General Hospital, Melanoma Institute Australia, Laura and Isaac Perlmutter Cancer Center, NYU School of Medicine, Georgetown University Medical Center,
Abstract
Next generation sequencing reveals targetable mutations in multiple sarcoma histologies.Org: Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Vanderbilt University School of Medicine, Vander Ingram Cancer Center, Division of Epidemiology and Community Health,
Abstract
Commercial vs. Medicaid insurance and use of high-priced anticancer treatments.Org: Memorial Sloan Kettering Cancer Center, Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Vanderbilt University School of Medicine, UNC Gillings School of Global Public Health,
Abstract
Nature and management of melanoma recurrences following adjuvant anti-PD-1 (PD1) therapy.Org: Melanoma Institute Australia, Netherlands Cancer Institute (NKI), Department of Dermatology, APHP St Louis, Alfred Health,